These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27817074)

  • 1. Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL.
    Hu J; Feng M; Liu ZL; Liu Y; Huang ZL; Li H; Feng WL
    Tumour Biol; 2016 Nov; ():. PubMed ID: 27817074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
    de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
    Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.
    Schürch C; Riether C; Matter MS; Tzankov A; Ochsenbein AF
    J Clin Invest; 2012 Feb; 122(2):624-38. PubMed ID: 22232214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
    Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
    [No Abstract]   [Full Text] [Related]  

  • 8. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
    Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
    Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
    Zhou Z; Liu T; Zhang J
    Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of gemcitabine on granulocyte colony-stimulating factor receptor and bcr/abl mRNA in patients with chronic myeloid leukemia].
    Liu D; Wang F; Sun L; Liu LX; Liu YF; Ling Z; Han XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1168-71. PubMed ID: 21129254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
    Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
    N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.